MAIA Bio Presents at J.P. Morgan Healthcare Conference
Ticker: MAIA · Form: 8-K · Filed: Feb 5, 2025 · CIK: 1878313
| Field | Detail |
|---|---|
| Company | Maia Biotechnology, INC. (MAIA) |
| Form Type | 8-K |
| Filed Date | Feb 5, 2025 |
| Risk Level | medium |
| Pages | 2 |
| Reading Time | 3 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: healthcare-conference, pipeline-update, biotechnology
Related Tickers: MAIA
TL;DR
MAIA Bio at JPM conference, talking cancer drug TH101 and 2025 plans.
AI Summary
On February 4, 2025, MAIA Biotechnology, Inc. announced its participation in the 36th Annual J.P. Morgan Healthcare Conference. The company presented its pipeline, including its lead drug candidate, TH101, for the treatment of cancer. MAIA Biotechnology also discussed its strategic priorities for 2025, focusing on advancing its clinical trials and exploring potential partnerships.
Why It Matters
Participation in a major healthcare conference like J.P. Morgan's provides MAIA Biotechnology with a platform to showcase its progress and pipeline to investors and potential partners, potentially influencing future funding and collaborations.
Risk Assessment
Risk Level: medium — Biotechnology companies often carry medium risk due to the inherent uncertainties in drug development and clinical trials.
Key Players & Entities
- MAIA Biotechnology, Inc. (company) — Registrant
- 36th Annual J.P. Morgan Healthcare Conference (event) — Conference attended
- TH101 (drug_candidate) — Lead drug candidate for cancer treatment
- February 4, 2025 (date) — Date of event
FAQ
What was the primary purpose of MAIA Biotechnology's participation in the J.P. Morgan Healthcare Conference?
MAIA Biotechnology participated to present its pipeline, including its lead drug candidate TH101 for cancer treatment, and discuss its strategic priorities for 2025.
When did MAIA Biotechnology present at the conference?
MAIA Biotechnology presented on February 4, 2025.
What is MAIA Biotechnology's lead drug candidate mentioned in the filing?
The company's lead drug candidate mentioned is TH101, intended for the treatment of cancer.
What are MAIA Biotechnology's strategic priorities for 2025?
The company's strategic priorities for 2025 include advancing its clinical trials and exploring potential partnerships.
Which specific conference did MAIA Biotechnology attend?
MAIA Biotechnology attended the 36th Annual J.P. Morgan Healthcare Conference.
Filing Stats: 672 words · 3 min read · ~2 pages · Grade level 11.2 · Accepted 2025-02-05 07:30:40
Filing Documents
- form8-k.htm (8-K) — 42KB
- ex99-1.htm (EX-99.1) — 19KB
- ex99-2.htm (EX-99.2) — 22KB
- ex99-2_001.jpg (GRAPHIC) — 223KB
- ex99-2_002.jpg (GRAPHIC) — 459KB
- ex99-2_003.jpg (GRAPHIC) — 346KB
- ex99-2_004.jpg (GRAPHIC) — 258KB
- ex99-2_005.jpg (GRAPHIC) — 95KB
- ex99-2_006.jpg (GRAPHIC) — 222KB
- ex99-2_007.jpg (GRAPHIC) — 156KB
- ex99-2_008.jpg (GRAPHIC) — 380KB
- ex99-2_009.jpg (GRAPHIC) — 277KB
- ex99-2_010.jpg (GRAPHIC) — 93KB
- ex99-2_011.jpg (GRAPHIC) — 329KB
- ex99-2_012.jpg (GRAPHIC) — 304KB
- ex99-2_013.jpg (GRAPHIC) — 279KB
- ex99-2_014.jpg (GRAPHIC) — 266KB
- ex99-2_015.jpg (GRAPHIC) — 108KB
- ex99-2_016.jpg (GRAPHIC) — 273KB
- ex99-2_017.jpg (GRAPHIC) — 258KB
- ex99-2_018.jpg (GRAPHIC) — 271KB
- ex99-2_019.jpg (GRAPHIC) — 166KB
- ex99-2_020.jpg (GRAPHIC) — 260KB
- ex99-2_021.jpg (GRAPHIC) — 231KB
- ex99-2_022.jpg (GRAPHIC) — 95KB
- ex99-2_023.jpg (GRAPHIC) — 220KB
- ex99-2_024.jpg (GRAPHIC) — 319KB
- ex99-2_025.jpg (GRAPHIC) — 233KB
- ex99-2_026.jpg (GRAPHIC) — 288KB
- ex99-2_027.jpg (GRAPHIC) — 274KB
- ex99-2_028.jpg (GRAPHIC) — 127KB
- ex99-2_029.jpg (GRAPHIC) — 77KB
- ex99-2_030.jpg (GRAPHIC) — 314KB
- 0001493152-25-004945.txt ( ) — 10173KB
- maia-20250204.xsd (EX-101.SCH) — 3KB
- maia-20250204_lab.xml (EX-101.LAB) — 33KB
- maia-20250204_pre.xml (EX-101.PRE) — 24KB
- form8-k_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Dated: February 5, 2025 MAIA BIOTECHNOLOGY, INC. By: /s/ Vlad Vitoc Name: Vlad Vitoc Title: Chief Executive Officer 3